Chondrosarcoma is the second most common surgically treated primary bone sarcoma. Despite a large number of scientific papers in the literature, there is still significant controversy about diagnostics, treatment of the primary tumour, subtypes, and complications. Therefore, consensus on its day-to-day treatment decisions is needed. In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) attempted to gain global consensus from 300 delegates from over 50 countries. The meeting focused on these critical areas and aimed to generate consensus statements based on evidence amalgamation and expert opinion from diverse geographical regions. In parallel, periprosthetic joint infection (PJI) in oncological reconstructions poses unique challenges due to factors such as adjuvant treatments, large exposures, and the complexity of surgery. The meeting debated two-stage revisions, antibiotic prophylaxis, managing acute PJI in patients undergoing chemotherapy, and defining the best strategies for wound management and allograft reconstruction. The objectives of the meeting extended beyond resolving immediate controversies. It sought to foster global collaboration among specialists attending the meeting, and to encourage future research projects to address unsolved dilemmas. By highlighting areas of disagreement and promoting collaborative research endeavours, this initiative aims to enhance treatment standards and potentially improve outcomes for patients globally. This paper sets out some of the controversies and questions that were debated in the meeting. Cite this article:
Socioeconomic and racial disparities have been recognized as impacting the care of patients with cancer, however there are a lack of data examining the impact of these disparities on patients with bone sarcoma. The purpose of this study was to examine socioeconomic and racial disparities that impact the oncological outcomes of patients with bone sarcoma. We reviewed 4,739 patients diagnosed with primary bone sarcomas from the Surveillance, Epidemiology and End Results (SEER) registry between 2007 and 2015. We examined the impact of race and insurance status associated with the presence of metastatic disease at diagnosis, treatment outcome, and overall survival (OS).Aims
Methods
Bone marrow-derived mesenchymal stem cells obtained from bone marrow aspirate concentrate (BMAC) with platelet-rich plasma (PRP), has been used as an adjuvant to hip decompression. Early results have shown promise for hip preservation in patients with osteonecrosis (ON) of the femoral head. The purpose of the current study is to examine the mid-term outcome of this treatment in patients with precollapse corticosteroid-induced ON of the femoral head. In all, 22 patients (35 hips; 11 males and 11 females) with precollapse corticosteroid-induced ON of the femoral head underwent hip decompression combined with BMAC and PRP. Mean age and BMI were 43 years (SD 12) and 31 kg/m² (SD 6), respectively, at the time of surgery. Survivorship free from femoral head collapse and total hip arthroplasty (THA) and risk factors for progression were evaluated at minimum five-years of clinical follow-up with a mean follow-up of seven years (5 to 8).Aims
Methods
In the lower extremity, lymphedema is characterized by fluid buildup and swelling which can lead to fibrosis of the skin and recurring soft-tissue infections. Risk factors include obesity, older age, lower extremity surgery, and radiotherapy. There is currently a paucity of data examining the impact of lymphedema in primary total knee arthroplasty (TKA). The purpose of this study was to review outcomes following primary TKA performed in patients with lymphedema compared to a matched cohort with primary osteoarthritis. Over a 19-year period (1998–2016), 144 patients underwent primary TKA with a preceding diagnosis of ipsilateral lymphedema (Table 1). There were 114 (79%) females, a mean age of 69 years, and mean BMI of 37.1 kg/m2. Mean follow-up was 7-years (range 2–17 years). A blinded analyst completed a 1:2 match of patients with lymphedema to a group of patients without lymphedema undergoing primary TKA for osteoarthritis during the same period. Matching criteria included sex, age, date of surgery, and BMI. Matched controls included 228 (79%) females along with a mean age and BMI of 69 and 36.4 kg/m2. The mean follow-up for the comparison cohort was 8 years (range 2–18 years). There were no significant differences between groups on the evaluated baseline parameters. Results: Patients with a history of lymphedema were at a significantly increased risk of revision TKA (HR 7.60, P<0.001), reoperation for any cause (HR 2.87, P<0.001), and postoperative infection (HR 6.19, P<0.001). Patients with lymphedema were also at increased risk for periprosthetic fracture (p=0.04) and tibial component loosening (p=0.01). Morbid obesity increased the risk of reoperation (HR 2.11, p=0.02) and trended toward increased risk of revision TKA (HR 2.29, p=0.059) and infection (HR 2.37, p=0.06). Discussion: Patients with lymphedema are at significantly increased risk of revision, reoperation, and infection following primary TKA. This data highlights the need for appropriate patient counseling in this population and optimization of lymphedema management before and after TKA.Introduction
Methods
Bilateral total knee arthroplasty (TKA) can be performed under a single-anesthetic (SA) or staged under a two-anesthetic (TA) technique. Recently, our institution began piloting a two-surgeon team SA method for bilateral TKA. The purpose of this study was to compare the inpatient costs and clinical outcomes in the first 90 days after surgery between the team SA, single-surgeon SA, and single-surgeon TA approaches for bilateral TKA. All primary TKA performed from 2007–2017 by the two participating surgeons for each of the 3 groups of interest were identified: team SA (N=42 patients; 84 knees), single-surgeon SA (N=146 patients; 292 knees), single-surgeon TA (N=242 patients; 484 knees). No patients were lost to follow-up.Introduction
Methods
